Bruce Power has received approval from the Canadian Nuclear Safety Commission (CNSC) to take the next step toward new isotope production, to become the first power reactor globally to commercially produce Lutetium-177.

“This project is an innovative partnership between Bruce Power, IsoGen, Saugeen Ojibway Nation (SON) and ITM and is a game changer for the supply of medical isotopes to the global medical community in the fight against cancer,” said James Scongack, Bruce Power Chief Development Officer and EVP Operational Services. “This is another important step forward to utilize our CANDU reactors to provide new large-scale capacity for production in the medical isotope supply chain, cementing Canada’s place as a global isotope superpower.” Isogen is a joint venture between Framatome and Kinectrics to enable the use of CANDU reactors to produce medical isotopes needed to treat and diagnose patients with serious diseases worldwide.

“The Framatome team conducted extensive research and development in Canada and modified German technology for use in a CANDU reactor, which resulted in the first isotope production system in a power reactor for commercial production of therapeutic medical isotopes,” said Curtis Van Cleve, President and CEO of Framatome Canada Ltd.

To read more please visit:

Bruce Power Receives regulatory Approval for New Lifesaving Medical Isotope production

Source: brucepower